Drug related morbidity and mortality updating the cost of illness
Patients referred to the psychiatric unit for evaluation, patients visiting on outpatient basis and patients who died during hospital stay were excluded from the study.
Demographic information, number of drugs taken, duration of hospital stay and laboratory investigations were obtained from the patients’ and clinical records.
Mean and standard deviation was used to summarize age and number of drugs taken.
All prescriptions of the study population were screened for DRPs such as adverse drug reactions (ADRs) and potential drug-drug interactions (p DDIs) by using computerized database system.Out of 120 patients, 19 patients had observed 26 DRPs.Drug-related problems (DRPs) are events involving drug therapy that actually or potentially interfere with desired health outcomes. DRPs are prevalent and cause considerable patient morbidity and mortality, as well as increased healthcare cost.[2,3,4] Antidepressants are the third ranked therapeutic class in global pharmaceutical sales, totaling USD 17.1 billion and growing at a rate of 5% annually. In addition to treating depressive disorders, antidepressant drugs are increasingly used to treat other illnesses, including anxiety disorders, chronic pain, and eating disorders. In many cases, antidepressant drugs are used concurrently with other medications, thus exposing patients to potential harm owing to adverse drug reactions (ADRs).RESULTS: Out of 120 patients, 19 patients had observed 26 DRPs.Out of 33 patients, 19 patients had observed 26 ADRs and 14 patients had observed 24 p DDIs. Female patients outnumbered the male patients, in which 12 women constitute 10% followed by men 7 (5.83%).